Bora Pharmaceuticals is reaping the rewards of its U.S. expansion strategy, with September revenue surging to a record NT$2.024 billion (US$63.8 million), nearly doubling year-on-year. The Taiwanese biotech firm’s aggressive push into the contract development and manufacturing organization (CDMO) sector is paying off, propelling its first nine months’ revenue to NT$13.499 billion, up 22.79% from the previous year.
The company’s third-quarter performance was particularly strong, with revenue reaching NT$5.615 billion, boosted by the integration of its U.S. operations. This marks Bora’s sixth consecutive month of year-over-year growth.
In a strategic move, Bora appointed JD Mowery, formerly of KBI Biopharma, to lead its global CDMO business operations. This appointment underscores Chairman Bobby Sheng’s ambition to position Bora among the world’s top ten CDMO companies.
The firm’s growth is further fueled by its diversification into health and nutrition products, including exclusive distribution deals with Shionogi and the expansion of its own Dr. Bora Drinks brand.
While Bora’s rapid expansion and ambitious targets are impressive, investors should remain cautious about the sustainability of this growth trajectory in the competitive biotech landscape.
